These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 18333368)
1. Pathogenic role of abnormal fatty acids and adipokines in the portal flow. Relevance for metabolic syndrome, hepatic steatosis and steatohepatitis. Brudaşcă I; Cucuianu M Rom J Intern Med; 2007; 45(2):149-57. PubMed ID: 18333368 [TBL] [Abstract][Full Text] [Related]
2. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Julius U Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):246-50. PubMed ID: 12951628 [TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and renal failure: similarities and differences. Kaysen GA Panminerva Med; 2006 Sep; 48(3):151-64. PubMed ID: 17122751 [TBL] [Abstract][Full Text] [Related]
4. Hemostasis alterations in metabolic syndrome (review). Palomo I; Alarcón M; Moore-Carrasco R; Argilés JM Int J Mol Med; 2006 Nov; 18(5):969-74. PubMed ID: 17016629 [TBL] [Abstract][Full Text] [Related]
6. PPAR agonists in the treatment of insulin resistance and associated arterial disease. Camejo G Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596 [TBL] [Abstract][Full Text] [Related]
7. Adipokines in liver diseases. Marra F; Bertolani C Hepatology; 2009 Sep; 50(3):957-69. PubMed ID: 19585655 [TBL] [Abstract][Full Text] [Related]
8. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Verna EC; Berk PD Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of disease progression in nonalcoholic fatty liver disease. Jou J; Choi SS; Diehl AM Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293 [TBL] [Abstract][Full Text] [Related]
11. The role of the lipogenic pathway in the development of hepatic steatosis. Postic C; Girard J Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625 [TBL] [Abstract][Full Text] [Related]
16. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. van de Woestijne AP; Monajemi H; Kalkhoven E; Visseren FL Obes Rev; 2011 Oct; 12(10):829-40. PubMed ID: 21749607 [TBL] [Abstract][Full Text] [Related]
17. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799 [TBL] [Abstract][Full Text] [Related]
18. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Adiels M; Olofsson SO; Taskinen MR; Borén J Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848 [TBL] [Abstract][Full Text] [Related]
19. Reverse cholesterol transport and atherosclerosis. A mini review. Cucuianu M; Coca M; Hâncu N Rom J Intern Med; 2007; 45(1):17-27. PubMed ID: 17966439 [TBL] [Abstract][Full Text] [Related]
20. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Musso G; Gambino R; De Michieli F; Biroli G; Fagà E; Pagano G; Cassader M Ann Med; 2008; 40(5):383-94. PubMed ID: 18484349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]